Honest, research-backed journalism on ivermectin, fenbendazole, HCQ, and your right to medical sovereignty. Updated daily.
Azithromycin was long the go-to single-dose chlamydia treatment, but new evidence has shifted guidance toward doxycycline. Here's what changed, why, and what remains true.
Azithromycin's short course isn't a shortcut — it reflects unique pharmacokinetics that let the drug keep working long after the last pill.
Long-term, low-dose azithromycin reduces flare-ups in COPD and bronchiectasis in well-conducted trials—but the benefit carries real trade-offs worth understanding.
Azithromycin lingers in tissues long after blood levels fall, thanks to cellular trapping and immune-cell transport. Here's the real pharmacology behind it.
Streptococcus pneumoniae has developed real, well-documented resistance to azithromycin and related macrolides. Here is what the evidence shows about how and why.
Azithromycin carries a recognized but small risk of heart rhythm changes. Here is what the actual research shows, and who should discuss it with a physician.
Azithromycin's interactions differ by formulation and by drug. Here is what the actual pharmacokinetic and outcomes research shows.
Azithromycin, clarithromycin, and erythromycin share one ribosomal target but differ sharply in chemistry, dosing, and safety.
Azithromycin remains useful for community-acquired pneumonia, but rising resistance has narrowed its role. Here's what current guidelines and evidence show.